Identifying the real-world challenges of dysplasia surveillance in inflammatory bowel disease: a retrospective cohort study in a tertiary health network

被引:2
|
作者
Elford, Alexander T. T. [1 ,2 ,4 ]
Hirsch, Ryan [1 ]
McKay, Owen M. M. [1 ]
Browne, Mitchell [1 ]
Moore, Gregory T. T. [1 ,3 ]
Bell, Sally [1 ,3 ]
Swan, Michael [1 ,3 ]
机构
[1] Monash Hlth, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic, Australia
[4] Gastroenterol Dept, 300 Grattan St, Parkville, Vic 3050, Australia
关键词
inflammatory bowel disease; dysplasia; dye chromoendoscopy; PRIMARY SCLEROSING CHOLANGITIS; WHITE-LIGHT ENDOSCOPY; ULCERATIVE-COLITIS; COLORECTAL-CANCER; TARGETED BIOPSIES; RISK; COLONOSCOPY; NEOPLASIA; CHROMOENDOSCOPY; CARCINOMA;
D O I
10.1111/imj.16102
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundDysplasia surveillance in inflammatory bowel disease (IBD) is often suboptimal and deviates from guidelines. AimsTo assess dysplasia surveillance behaviours and adherence to guidelines amongst a large tertiary teaching health network with a specialised IBD unit to identify areas where dysplasia surveillance could be improved. MethodsA retrospective audit of IBD surveillance colonoscopy practice over an 18-month period was performed using the Provation Endoscopy Database and the hospital's primary sclerosing cholangitis database. ResultsThe audit identified 115 dysplasia surveillance colonoscopies. A total of 37% of index dysplasia colonoscopies were outside recommended guidelines. A total of 10% had inadequate bowel preparation and only 40% had excellent bowel preparation. A total of 28% of patients underwent dye-based chromoendoscopy and 69% underwent high-definition white-light endoscopy. Dye chromoendoscopy was more likely to be used by IBD specialists than interventional endoscopists (P = 0.008) and other endoscopists (P = 0.004). Only IBD specialists and interventional endoscopists used dye chromoendoscopy. Dysplasia or colorectal cancer was detected in 3.4% of the colonoscopies. Overall, the several dysplasia examinations were lower than expected. ConclusionsDysplasia surveillance in the IBD population remains an area of improvement given the current national guidelines. IBD specialists are more likely to perform dye chromoendoscopy than other endoscopists/gastroenterologists. Dysplasia rates in this real-world contemporary setting are less than expected in historical studies and may represent improvements in IBD management principles and medications.
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [41] Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases
    Viola, Anna
    Muscianisi, Marco
    Macaluso, Fabio S.
    Ventimiglia, Marco
    Cappello, Maria
    Privitera, Antonino C.
    Magnano, Antonio
    Pluchino, Dario
    Magri, Giovanni
    Ferracane, Concetta
    Mocciaro, Filippo
    Garufi, Serena
    Giuffrida, Enrica
    Costantino, Giuseppe
    Fiocco, Gabriele
    Grova, Mauro
    Guida, Laura
    Alibrandi, Angela
    Orlando, Ambrogio
    Fries, Walter
    JGH OPEN, 2021, 5 (03): : 364 - 370
  • [42] Identifying Patients With Inflammatory Bowel Disease on Twitter and Learning From Their Personal Experience: Retrospective Cohort Study
    Stemmer, Maya
    Parmet, Yisrael
    Ravid, Gilad
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2022, 24 (08)
  • [43] The Clinical Course of Bowel Urgency Severity Among Patients with Inflammatory Bowel Disease-A Real-World Study
    Lewis, James D.
    Gibble, Theresa Hunter
    Shan, Mingyang
    Zhou, Xian
    Naegeli, April N.
    Dawwas, Ghadeer K.
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (03) : 403 - 412
  • [44] Effectiveness and Safety Analysis of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study
    Wu, H.
    Su, T.
    Wu, L.
    Zhi, M.
    Yao, J.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1216 - i1217
  • [45] PRECISION DOSING TEST FOR OPTIMIZING ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EVIDENCE STUDY
    Hanauer, Stephen B.
    Torres, Esther A.
    Swaminath, Arun
    Lee, Thomas C.
    Rabizadeh, Shervin
    Check, Morgan S.
    Barrett, Terrence
    Chapman, Casey
    Arai, Ronen
    Hashash, Jana G.
    Butnariu, Madalina
    Meister, Thomas
    Kinnucan, Jami A.
    Yen, Eugene F.
    Stein, Daniel J.
    Sinh, Preetika
    Ziring, David
    Sharposhnikov, Rimma
    Qazi, Taha
    Yarur, Andres
    Han, Patricia Aragon
    Abraham, Bincy P.
    GASTROENTEROLOGY, 2024, 166 (05) : S832 - S832
  • [46] An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study
    Wu, Hongzhen
    Xie, Tingting
    Yu, Qiao
    Su, Tao
    Zhang, Min
    Wu, Luying
    Wang, Xiaoling
    Peng, Xiang
    Zhi, Min
    Yao, Jiayin
    BIOMEDICINES, 2025, 13 (01)
  • [47] PRECISION DOSING TEST IN OPTIMIZING INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: A REAL-WORLD EVIDENCE STUDY
    Abraham, Bincy P.
    Fatima, Ayesha
    Battat, Robert J.
    Carroll, Kristin
    Torres, Esther A.
    Rabizadeh, Shervin
    Ziring, David
    Gohndrone, Judith
    Lum, Donald
    Arai, Ronen
    Ali, Tauseef
    Allen, Mark J.
    Condino, Adria A.
    Stein, Daniel J.
    Pandey, Akash
    Barrett, Terrence
    Ritter, Timothy E.
    Bray, Harry
    Hanauer, Stephen B.
    Dervieux, Thierry
    Colombel, Jean Frederic
    GASTROENTEROLOGY, 2023, 164 (06) : S1111 - S1111
  • [48] Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center
    Allamneni, Chaitanya
    Venkata, Krishna
    Yun, Huifeng
    Xie, Fenglong
    DeLoach, Lindsey
    Malik, Talha A.
    GASTROENTEROLOGY RESEARCH, 2018, 11 (01) : 41 - 45
  • [49] The yield of dysplasia and serrated lesions in a single-centre tertiary inflammatory bowel disease cohort
    Yeaman, Fiona
    Thin, Lena
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [50] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Peeyush Kumar
    Sudheer K. Vuyyuru
    Bhaskar Kante
    Saurabh Kedia
    Pabitra Sahu
    Mukesh Kumar Ranjan
    Sandeep Mundhra
    Rithvik Golla
    Mukesh Kumar
    Shubi Virmani
    Anvita Gupta
    Nidhi Yadav
    Govind Makharia
    Vineet Ahuja
    Indian Journal of Gastroenterology, 2022, 41 : 446 - 455